Stefan Willmann

5.0k total citations
93 papers, 3.8k citations indexed

About

Stefan Willmann is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Pharmacology. According to data from OpenAlex, Stefan Willmann has authored 93 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pediatrics, Perinatology and Child Health, 21 papers in Pharmacology and 20 papers in Pharmacology. Recurrent topics in Stefan Willmann's work include Pharmaceutical studies and practices (21 papers), Pharmacogenetics and Drug Metabolism (20 papers) and Antibiotics Pharmacokinetics and Efficacy (20 papers). Stefan Willmann is often cited by papers focused on Pharmaceutical studies and practices (21 papers), Pharmacogenetics and Drug Metabolism (20 papers) and Antibiotics Pharmacokinetics and Efficacy (20 papers). Stefan Willmann collaborates with scholars based in Germany, United States and Canada. Stefan Willmann's co-authors include Andrea N. Edginton, Walter Schmitt, Jörg Lippert, Jennifer Dressman, Thomas Eißing, Kirstin Thelen, Katrin Coboeken, Juri Solodenko, Christoph Niederalt and Jörg Keldenich and has published in prestigious journals such as Blood, Kidney International and Journal of Medicinal Chemistry.

In The Last Decade

Stefan Willmann

91 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefan Willmann Germany	32	1.1k	1.0k	705	626	543	93	3.8k
Jörg Lippert Germany	28	579 0.5×	755 0.7×	388 0.6×	472 0.8×	630 1.2×	75	3.0k
Andrea N. Edginton Canada	33	1.1k 1.1×	830 0.8×	778 1.1×	430 0.7×	507 0.9×	140	3.8k
Ping Zhao United States	36	682 0.6×	1.1k 1.1×	328 0.5×	1.3k 2.0×	626 1.2×	96	3.5k
Shiew‐Mei Huang United States	47	1.3k 1.2×	2.4k 2.3×	712 1.0×	1.8k 2.9×	1.1k 2.1×	147	5.7k
Masoud Jamei United Kingdom	45	1.4k 1.3×	2.1k 2.1×	901 1.3×	1.8k 2.8×	1.0k 1.9×	133	6.1k
Lawrence J. Lesko United States	51	1.3k 1.2×	2.2k 2.1×	882 1.3×	1.4k 2.2×	1.4k 2.6×	172	7.3k
Neil Parrott Switzerland	37	713 0.7×	1.5k 1.4×	573 0.8×	1.3k 2.1×	1.0k 1.9×	125	4.5k
Roger K. Verbeeck Belgium	36	807 0.8×	1.4k 1.3×	1.2k 1.7×	817 1.3×	647 1.2×	156	4.7k
Thomas M. Ludden United States	32	766 0.7×	687 0.7×	612 0.9×	492 0.8×	505 0.9×	158	4.1k
Thierry Lavé Switzerland	35	364 0.3×	1.3k 1.3×	339 0.5×	1.1k 1.7×	682 1.3×	68	3.0k

Countries citing papers authored by Stefan Willmann

Since Specialization

Citations

This map shows the geographic impact of Stefan Willmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Willmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Willmann more than expected).

Fields of papers citing papers by Stefan Willmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Willmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Willmann. The network helps show where Stefan Willmann may publish in the future.

Co-authorship network of co-authors of Stefan Willmann

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Willmann. A scholar is included among the top collaborators of Stefan Willmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Willmann. Stefan Willmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Huijun, Kirstin Thelen, Frauke Friedrichs, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and Translational Science. 17(4). e13784–e13784. 7 indexed citations

Willmann, Stefan, Adam Lloyd, Rupert Austin, et al.. (2024). Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2137–2149. 1 indexed citations

Winkelmayer, Wolfgang C., Anthonie W.A. Lensing, Ravi Thadhani, et al.. (2024). A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International. 106(1). 145–153. 16 indexed citations

Moore, Kenneth Todd, et al.. (2023). The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development. The Journal of Clinical Pharmacology. 63(S2). S78–S84. 1 indexed citations

Willmann, Stefan, Ibrahim Ince, Maurice J. Ahsman, et al.. (2022). Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease. CPT Pharmacometrics & Systems Pharmacology. 11(8). 1111–1121. 6 indexed citations

Willmann, Stefan, et al.. (2022). Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatric Pulmonology. 58(3). 908–917.

Palumbo, Joseph S., Anthonie W.A. Lensing, Leonardo R. Brandão, et al.. (2022). Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Advances. 6(22). 5821–5828. 8 indexed citations

Willmann, Stefan, Alexander Solms, Markus Jensen, et al.. (2021). PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics & Systems Pharmacology. 10(8). 890–901. 36 indexed citations

Willmann, Stefan, et al.. (2021). Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. Frontiers in Pharmacology. 12. 630904–630904. 8 indexed citations

10.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 1–11. 4 indexed citations

11.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 12–19. 11 indexed citations

12.

Dallmann, André, Ibrahim Ince, Michaela Meyer, et al.. (2017). Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clinical Pharmacokinetics. 56(11). 1303–1330. 96 indexed citations

13.

Eißing, Thomas, et al.. (2014). Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling. SpringerPlus. 3(1). 285–285. 13 indexed citations

14.

Eißing, Thomas, et al.. (2012). First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. Journal of Pharmacokinetics and Pharmacodynamics. 39(2). 195–203. 49 indexed citations

15.

Thelen, Kirstin, Katrin Coboeken, Stefan Willmann, et al.. (2011). Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. Journal of Pharmaceutical Sciences. 100(12). 5324–5345. 111 indexed citations

16.

Edginton, Andrea N., Frank‐Peter Theil, Walter Schmitt, & Stefan Willmann. (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology. 4(9). 1143–1152. 121 indexed citations

17.

Edginton, Andrea N. & Stefan Willmann. (2008). Physiology-Based Simulations of a Pathological Condition. Clinical Pharmacokinetics. 47(11). 743–752. 148 indexed citations

18.

Niederalt, Christoph, et al.. (2007). Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theoretical Biology and Medical Modelling. 4(1). 13–13. 48 indexed citations

19.

Schmitt, Walter & Stefan Willmann. (2005). Physiology-based pharmacokinetic modeling: ready to be used. Drug Discovery Today Technologies. 2(1). 125–132. 36 indexed citations

20.

Willmann, Stefan, et al.. (2003). Small-volume frequency-domain oximetry: phantom experiments and first in vivo results. Journal of Biomedical Optics. 8(4). 618–618. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact